The Presence of SDHB Mutations Should Modify Surgical Indications for Carotid Body Paragangliomas

Overview

Journal Ann Surg

Specialty General Surgery

Date 2013 Oct 31

PMID 24169168

Citations 30

Authors

Ryan J Ellis

Dhaval Patel

Tamara Prodanov

Naris Nilubol

Karel Pacak

Electron Kebebew

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to determine whether the genetic background of the disease should be incorporated into treatment decision making.

Background: Carotid body paragangliomas are rare tumors that often affect patients with genetic mutations of the succinate dehydrogenase complex (SDHx). Despite growing evidence that germ line genetic mutations alter the aggressiveness of paragangliomas, treatment decisions are currently based only on clinical symptoms and tumor size in patients with carotid body paragangliomas.

Methods: Retrospective analysis of 34 patients with carotid body paragangliomas who underwent genetic testing and surgical treatment. Recurrence was defined by the return of locoregional disease and/or development of distant metastases. Clinical characteristics and genetic testing results were analyzed as predictors of patient outcomes.

Results: Thirty-four patients underwent 41 primary carotid body paraganglioma resections (median follow-up time of 42 months, range: 1-293). Overall survival was 91.2%. Twelve patients had germ line mutations in SDHB, 17 in SDHD, and 5 carried no known mutation. Surgical resection of larger tumors was associated with higher operative complications (odds ratio: 5.4, P = 0.05). Tumor size at resection was significantly smaller in patients with SDHB mutations than in patients with non-SDHB mutations (2.1 vs 3.3 cm, P = 0.02). Patients with a mutation in the SDHB gene also had significantly worse disease-free survival compared with patients without an SDHB gene mutation (P = 0.03).

Conclusions: Mutations in the SDHB gene are associated with worse disease-free survival after resection in patients with carotid body paragangliomas despite earlier intervention. This suggests that a more aggressive surgical approach is warranted in patients with SDHB mutations.

Citing Articles

Management and follow-up strategies for patients with head and neck paraganglioma.

Richter S, Pacak K, Kunst H, Januszewicz A, Nolting S, Remde H Eur J Endocrinol. 2024; 191(4):389-398.

PMID: 39303070 PMC: 11443905. DOI: 10.1093/ejendo/lvae113.

Paragangliomas of the Head and Neck: A Review of the Latest Diagnostic and Treatment Methods.

Palade D, Hainarosie R, Zamfir A, Vrinceanu D, Pertea M, Tusaliu M Medicina (Kaunas). 2024; 60(6).

PMID: 38929531 PMC: 11205799. DOI: 10.3390/medicina60060914.

The Management of Phaeochromocytomas and Paragangliomas in the Era of Precision Medicine: Where Are We Now? Evidence-Based Systemic Treatment Options and Future Cluster Oriented Perspectives.

Bracigliano A, Marretta A, Guerrera L, Simioli R, Clemente O, Granata V Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543140 PMC: 10975789. DOI: 10.3390/ph17030354.

Unilateral synchronous masses of the neck revealing a malignant Carotid Body Tumor: A case report and literature review.

Sallom M, Al Laham O, Ghannam E, Ghannam M, Mohammad A Int J Surg Case Rep. 2023; 105:108025.

PMID: 36989635 PMC: 10074580. DOI: 10.1016/j.ijscr.2023.108025.

Paraganglioma of the Head and Neck: A Review.

Sandow L, Thawani R, Kim M, Heinrich M Endocr Pract. 2022; 29(2):141-147.

PMID: 36252779 PMC: 9979593. DOI: 10.1016/j.eprac.2022.10.002.

References

van Hulsteijn L, Dekkers O, Hes F, Smit J, Corssmit E . Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis. J Med Genet. 2012; 49(12):768-76. DOI: 10.1136/jmedgenet-2012-101192. View

Boedeker C, Neumann H, Maier W, Bausch B, Schipper J, Ridder G . Malignant head and neck paragangliomas in SDHB mutation carriers. Otolaryngol Head Neck Surg. 2007; 137(1):126-9. DOI: 10.1016/j.otohns.2007.01.015. View

Schwaber M, Glasscock M, Nissen A, Jackson C, Smith P . Diagnosis and management of catecholamine secreting glomus tumors. Laryngoscope. 1984; 94(8):1008-15. DOI: 10.1288/00005537-198408000-00002. View

Fruhmann J, Geigl J, Konstantiniuk P, Cohnert T . Paraganglioma of the carotid body: treatment strategy and SDH-gene mutations. Eur J Vasc Endovasc Surg. 2013; 45(5):431-6. DOI: 10.1016/j.ejvs.2013.01.018. View

Gimenez-Roqueplo A, Favier J, Rustin P, Rieubland C, Crespin M, Nau V . Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 2003; 63(17):5615-21. View

Pellitteri P, Rinaldo A, Myssiorek D, Jackson C, Bradley P, Devaney K . Paragangliomas of the head and neck. Oral Oncol. 2004; 40(6):563-75. DOI: 10.1016/j.oraloncology.2003.09.004. View

Zarnegar R, Kebebew E, Duh Q, Clark O . Malignant pheochromocytoma. Surg Oncol Clin N Am. 2006; 15(3):555-71. DOI: 10.1016/j.soc.2006.05.009. View

Boedeker C . Paragangliomas and paraganglioma syndromes. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2012; 10:Doc03. PMC: 3341580. DOI: 10.3205/cto000076. View

Schipper J, Boedeker C, Maier W, Neumann H . [Paragangliomas in the head-/neck region. I: Classification and diagnosis]. HNO. 2004; 52(6):569-74. DOI: 10.1007/s00106-003-1007-7. View

10.

Maier W, Marangos N, Laszig R . Paraganglioma as a systemic syndrome: pitfalls and strategies. J Laryngol Otol. 2000; 113(11):978-82. DOI: 10.1017/s0022215100145761. View

11.

Erickson D, Kudva Y, Ebersold M, Thompson G, Grant C, Van Heerden J . Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001; 86(11):5210-6. DOI: 10.1210/jcem.86.11.8034. View

12.

de Flines J, Jansen J, Elders R, Siemers M, Vriends A, Hes F . Normal life expectancy for paraganglioma patients: a 50-year-old cohort revisited. Skull Base. 2012; 21(6):385-8. PMC: 3312129. DOI: 10.1055/s-0031-1287681. View

13.

Jansen J, van den Berg R, Kuiper A, van der Mey A, Zwinderman A, Cornelisse C . Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. Cancer. 2000; 88(12):2811-6. View

14.

Matro J, Giubellino A, Pacak K . Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors. Horm Metab Res. 2013; 45(2):147-53. PMC: 3577956. DOI: 10.1055/s-0032-1331211. View

15.

Lee J, Barich F, Karnell L, Robinson R, Zhen W, Gantz B . National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer. 2002; 94(3):730-7. DOI: 10.1002/cncr.10252. View

16.

Neumann H, Pawlu C, Peczkowska M, Bausch B, McWhinney S, Muresan M . Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004; 292(8):943-51. DOI: 10.1001/jama.292.8.943. View

17.

Wangberg B, Muth A, Khorram-Manesh A, Jansson S, Nilsson O, Forssell-Aronsson E . Malignant pheochromocytoma in a population-based study: survival and clinical results. Ann N Y Acad Sci. 2006; 1073:512-6. DOI: 10.1196/annals.1353.054. View

18.

ORiordain D, Young Jr W, Grant C, Carney J, Van Heerden J . Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg. 1996; 20(7):916-21; discussion 922. DOI: 10.1007/s002689900139. View

19.

Pacak K, Eisenhofer G, Ahlman H, Bornstein S, Gimenez-Roqueplo A, Grossman A . Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab. 2007; 3(2):92-102. DOI: 10.1038/ncpendmet0396. View

20.

Langerman A, Athavale S, Rangarajan S, Sinard R, Netterville J . Natural history of cervical paragangliomas: outcomes of observation of 43 patients. Arch Otolaryngol Head Neck Surg. 2012; 138(4):341-5. DOI: 10.1001/archoto.2012.37. View